Psyence Biomedical Plummets 6.85% Amid 45376% Surge in $300M Volume Jumps to 479th Market Rank on PsyLabs Ibogaine Breakthrough

Psyence Biomedical (PBM) fell 6.85% on July 31, with a trading volume of $300 million, a 45,376.31% increase from the previous day, ranking 479th in the market. The decline followed announcements from its strategic partner PsyLabs, which successfully produced a GMP-aligned Ibogaine Total Alkaloid extract. The high-purity extract, verified by a third-party lab, met microbial safety standards for food-grade consumption, marking a key milestone in psychedelic pharmaceutical development.

Psyence’s ongoing investment in PsyLabs since 2024 underscores the collaboration’s strategic importance. The breakthrough validates PsyLabs’ ability to produce scalable, compliant psychedelic APIs, aligning with Psyence’s focus on nature-derived treatments for mental health disorders. PsyLabs’ expansion of chemistry production facilities aims to meet rising global demand for compounds like Ibogaine HCL and Psilocybin Isolate, with products available to licensed research institutions worldwide.

A strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day delivered a 166.71% return from 2022 to the present, outperforming the benchmark return of 29.18% by 137.53%. This highlights the effectiveness of capturing market momentum despite recent fluctuations in stock rankings and trading volumes.